Abstract
Serum TNF-α and IL-17 levels are significantly increased in patients with CU compared to healthy age- and sex-matched controls. These findings have the potential to influence clinical guidelines for the diagnostic workup of CU to include testing the serum levels of TNF-α and IL-17.
Introduction
Chronic urticaria (CU) is a debilitating skin condition characterized by the persistent appearance of wheals (hives) and angioedema for over six weeks. While mast cells have long been considered the primary drivers of the disease, the underlying immunological mechanisms remain complex. Recent research has pointed toward immune dysregulation mediated by T lymphocytes—specifically Th1, Th2, and Th17 subsets—as a significant factor. However, individual studies often produce conflicting results regarding which cytokines are actually elevated in patients. This paper addresses this lack of consensus by performing a rigorous meta-analysis to identify which serum biomarkers reliably reflect CU disease activity, potentially moving the field toward more precise diagnostic workups.
Methods
The researchers conducted a systematic review following PRISMA guidelines, searching PubMed, EMBASE, and Web of Science through November 2024.
Out of 6,013 initial records, 50 studies were included, covering 22 different cytokines. The meta-analysis utilized a random-effects model with Hedges’ g to calculate pooled standardized mean differences (SMDs), accounting for potential bias in studies with small sample sizes. For studies reporting medians and ranges rather than means and standard deviations, validated mathematical methods were used to estimate the necessary statistics. Study quality was assessed using the National Heart, Lung, and Blood Institute (NHLBI) Quality Assessment Tool, with 88% of the included studies rated as "high quality."
Key Insights and Results
The meta-analysis highlights the Th17 pathway (specifically IL-17) as a major player in CU pathogenesis. IL-17 involves epithelial and endothelial cells, suggesting a broader inflammatory network than previously emphasized. Additionally, the study confirmed a significant link between CU and elevated TNF-α. Since TNF-α is released by skin mast cells and other inflammatory cells at lesion sites, it serves as a bridge between the traditional mast cell theory and the newer T-cell dysregulation theory.
The meta-analysis yielded two primary quantitative biomarkers for CU:
- TNF-α: Showed a significant pooled SMD of 1.40 (95% CI, 0.59–2.21).
- IL-17: Showed a significant pooled SMD of 1.43 (95% CI, 0.11–2.75).
Interestingly, IL-6 showed a strong trend toward elevation (SMD of 1.94), but because the confidence interval crossed zero (-0.11 to 3.99), it did not reach statistical significance in the pooled analysis, suggesting high variability between studies or specific patient subgroups.
Limitations and Future Work
The authors acknowledge several hurdles for clinical implementation, including assay heterogeneity (e.g., ELISA vs. multiplex assays) and the lack of differentiation between chronic induced urticaria and chronic spontaneous urticaria (CSU) in the reviewed literature. Furthermore, the field still lacks established "cut-off" values that a clinician could use for definitive diagnosis or severity assessment. Future work should focus on large-scale studies to determine these optimal cutoff levels and explore the sensitivity and specificity of these biomarkers in real-world clinical settings.
Conclusion
This systematic review and meta-analysis identifies TNF-α and IL-17 as the most consistent serum biomarkers for chronic urticaria. The findings suggest that T-cell dysregulation—specifically involving Th1 and Th17 pathways—plays a critical role in the disease, providing a strong case for including these cytokines in future clinical diagnostic panels.
Summary updated